



Virus-Like Particle (VLP) Vaccines

Guest Editors:

Dr. Eloisa Yuste

Institute of Health Carlos III,
ISCIII, National Microbiology
Centre, 28029 Madrid, Spain

Prof. Dr. James Binley

San Diego Biomedical Research
Institute, 3525 John Hopkins
Court, San Diego, CA 92121, USA

Deadline for manuscript
submissions:

closed (15 March 2023)

Message from the Guest Editors

Dear colleagues,

Virus-like particles (VLPs) have been shown to be safe to administer to animals and humans. In addition, VLPs have demonstrated the ability to stimulate both innate and adaptive immune responses. Moreover, their particulate structure favors absorption by antigen-presenting cells. These intrinsic immunological characteristics of VLPs, augmented by their self-adjuvant properties and demonstrated success as products to date, suggest potential for broad impact in the coming years.

This Special Issue aims to collect research articles, brief reports and communications on "virus-like particle (VLP) vaccines" in order to promote the knowledge and discussion about the various VLP formulations developed and modifications aimed at improving antigen display versatility, efficacy and stability. We look forward to receiving your contributions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com